| BIOAGENCY AG Patent applications |
| Patent application number | Title | Published |
|---|
| 20110129883 | INACTIVATION OF GENES OF THE MEP PATHWAY - The invention relates to cells and organisms as well as to methods for producing said cells and organisms, according to which intermediates of the mevalonate-independent pathway for isoprenoid biosynthesis (MEP pathway) are enriched by deleting or inactivating genes. The derivatives can also be enriched by using enzyme inhibitors. The enriched intermediates may be used as substrates in enzyme activity tests. The inventive cells and organisms and the enriched intermediates can further be used in the production of medicaments. | 06-02-2011 |
| 20110112054 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells - The present invention describes organophosphorus compounds of general formula (I) | 05-12-2011 |
| 20080318942 | Fredericamycin Derivatives - The invention relates to new fredericamycin derivatives, to pharmaceutical drugs containing them or their salts, and to the use of the fredericamycin derivatives for the treatment of diseases, especially tumor diseases. | 12-25-2008 |
| 20080249067 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells - The present invention describes organophosphorus compounds of general formula (I) | 10-09-2008 |
| 20080206267 | Inactivation Of Genes Of The Mep Pathway - The invention relates to cells and organisms as well as to methods for producing said cells and organisms, according to which intermediates of the mevalonate-independent pathway for isoprenoid biosynthesis (MEP pathway) are enriched by deleting or inactivating genes. The derivatives can also be enriched by using enzyme inhibitors. The enriched intermediates may be used as substrates in enzyme activity tests. The inventive cells and organisms and the enriched intermediates can further be used in the production of medicaments. | 08-28-2008 |
